SE0202311D0 - Novel compounds, cytotoxic preparations comprising said compounds, methods of manufacture of said preparations, as well as methods of treatment - Google Patents

Novel compounds, cytotoxic preparations comprising said compounds, methods of manufacture of said preparations, as well as methods of treatment

Info

Publication number
SE0202311D0
SE0202311D0 SE0202311A SE0202311A SE0202311D0 SE 0202311 D0 SE0202311 D0 SE 0202311D0 SE 0202311 A SE0202311 A SE 0202311A SE 0202311 A SE0202311 A SE 0202311A SE 0202311 D0 SE0202311 D0 SE 0202311D0
Authority
SE
Sweden
Prior art keywords
compounds
retinoyl
acid
methods
preparations
Prior art date
Application number
SE0202311A
Other languages
English (en)
Inventor
Oleg Strelchenok
Julian Aleksov
Original Assignee
Ardenia Investments Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ardenia Investments Ltd filed Critical Ardenia Investments Ltd
Priority to SE0202311A priority Critical patent/SE0202311D0/sv
Publication of SE0202311D0 publication Critical patent/SE0202311D0/sv
Priority to ES02783947.1T priority patent/ES2452540T3/es
Priority to US10/295,139 priority patent/US7030158B2/en
Priority to CNB028296087A priority patent/CN100360502C/zh
Priority to AU2002347747A priority patent/AU2002347747A1/en
Priority to PT27839471T priority patent/PT1534672E/pt
Priority to DK02783947.1T priority patent/DK1534672T3/da
Priority to EP02783947.1A priority patent/EP1534672B1/en
Priority to PCT/SE2002/002087 priority patent/WO2004009538A1/en
Priority to HK06100168.0A priority patent/HK1080447B/zh
Priority to CY20131100567T priority patent/CY1114788T1/el

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01Sulfonic acids
    • C07C309/02Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/17Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing carboxyl groups bound to the carbon skeleton
    • C07C309/18Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing carboxyl groups bound to the carbon skeleton containing amino groups bound to the same carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C313/00Sulfinic acids; Sulfenic acids; Halides, esters or anhydrides thereof; Amides of sulfinic or sulfenic acids, i.e. compounds having singly-bound oxygen atoms of sulfinic or sulfenic groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C313/02Sulfinic acids; Derivatives thereof
    • C07C313/04Sulfinic acids; Esters thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07Optical isomers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/09Geometrical isomers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/12Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/16Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
SE0202311A 2002-07-23 2002-07-23 Novel compounds, cytotoxic preparations comprising said compounds, methods of manufacture of said preparations, as well as methods of treatment SE0202311D0 (sv)

Priority Applications (11)

Application Number Priority Date Filing Date Title
SE0202311A SE0202311D0 (sv) 2002-07-23 2002-07-23 Novel compounds, cytotoxic preparations comprising said compounds, methods of manufacture of said preparations, as well as methods of treatment
PCT/SE2002/002087 WO2004009538A1 (en) 2002-07-23 2002-11-15 Retinol derivatives, their use in the treatment of cancer and for potentiating the efficacy of other cytotoxic agents
AU2002347747A AU2002347747A1 (en) 2002-07-23 2002-11-15 Retinol derivatives, their use in the treatment of cancer and for potentiating the efficacy of other cytotoxic agents
US10/295,139 US7030158B2 (en) 2002-07-23 2002-11-15 Therapeutic compounds
CNB028296087A CN100360502C (zh) 2002-07-23 2002-11-15 视黄醇衍生物、它们在治疗癌症和增强其它细胞毒性剂功效中的应用
ES02783947.1T ES2452540T3 (es) 2002-07-23 2002-11-15 Derivados de retinol, su uso en el tratamiento del cáncer y para potenciar la eficacia de otros agentes citotóxicos
PT27839471T PT1534672E (pt) 2002-07-23 2002-11-15 Derivados de retinol, a sua utilização no tratamento do cancro e para potenciar a eficácia de outros agentes citotóxicos
DK02783947.1T DK1534672T3 (da) 2002-07-23 2002-11-15 Retinolderivater, deres anvendelse til behandling af cancer og til potensering af virkningen af andre cytotoksi¬ske midler
EP02783947.1A EP1534672B1 (en) 2002-07-23 2002-11-15 Retinol derivatives, their use in the treatment of cancer and for potentiating the efficacy of other cytotoxic agents
HK06100168.0A HK1080447B (zh) 2002-07-23 2006-01-04 視黃醇衍生物、它們在治療癌症和增强其它細胞毒性劑功效中的應用
CY20131100567T CY1114788T1 (el) 2002-07-23 2013-07-05 Παραγωγα ρετινολης, χρηση αυτων στη θεραπεια καρκινου και για ενισχυση της αποτελεσματικοτητας αλλων κυτταροτοξικων παραγοντων

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0202311A SE0202311D0 (sv) 2002-07-23 2002-07-23 Novel compounds, cytotoxic preparations comprising said compounds, methods of manufacture of said preparations, as well as methods of treatment

Publications (1)

Publication Number Publication Date
SE0202311D0 true SE0202311D0 (sv) 2002-07-23

Family

ID=20288630

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0202311A SE0202311D0 (sv) 2002-07-23 2002-07-23 Novel compounds, cytotoxic preparations comprising said compounds, methods of manufacture of said preparations, as well as methods of treatment

Country Status (5)

Country Link
US (1) US7030158B2 (sv)
DK (1) DK1534672T3 (sv)
ES (1) ES2452540T3 (sv)
PT (1) PT1534672E (sv)
SE (1) SE0202311D0 (sv)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009078756A1 (en) * 2007-12-19 2009-06-25 Ardenia Investments, Ltd. Drug delivery system for administration of a water soluble, cationic and amphiphilic pharmaceutically active substance
WO2009078754A1 (en) * 2007-12-19 2009-06-25 Ardenia Investments, Ltd. Drug delivery system for administration of poorly water soluble pharmaceutically active substances
WO2009078755A1 (en) * 2007-12-19 2009-06-25 Ardenia Investments, Ltd. Drug delivery system for administration of a water soluble, cationic and amphiphilic pharmaceutically active substance
EP3386947B1 (en) * 2015-12-09 2021-05-19 Oasmia Pharmaceutical AB Method for producing n-retinoylaminoalkane sulfonic acid

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4032187C2 (de) 1990-10-10 1995-03-30 Gradinger F Hermes Pharma N-Retinoyl-L-aminomercapto-Verbindungen und Zwischenprodukte, Verfahren zu ihrer Herstellung und ihre Verwendung
SE0101702D0 (sv) * 2001-05-15 2001-05-15 Ardenia Investments Ltd Novel potentiating compounds

Also Published As

Publication number Publication date
US7030158B2 (en) 2006-04-18
ES2452540T3 (es) 2014-04-01
DK1534672T3 (da) 2013-07-29
US20040048923A1 (en) 2004-03-11
PT1534672E (pt) 2013-08-05

Similar Documents

Publication Publication Date Title
NO20075136L (no) Nye liposompreparater
NZ591810A (en) Pharmaceutical compositions and related methods of delivery the composition comprises a medium chain fatty acid
UA108363C2 (uk) Похідні імінотіадіазиндіоксиду як інгібітори bace, композиція на їх основі і їх застосування
EA201171376A1 (ru) Производные тиено[2,3-b]пиридина в качестве ингибиторов репликации вируса
HRP20120803T1 (hr) Prolijekovi alkilatora fosforamidata
UA107578C2 (uk) Комбінована терапія при лікуванні діабету
BRPI0409427A (pt) composto, uso do mesmo, composição farmacêutica, método de tratamento de um humano sofrendo de uma doença hiperproliferativa, e, processo para a preparação de um composto ou de um sal, éster ou pró-droga farmaceuticamente aceitáveis do mesmo
WO2005000232A3 (en) Six membered amino-amide derivatives as angiogenesis inhibitors
EA200801580A1 (ru) Новые производные пирониндола и способ их получения
EA201171088A1 (ru) Лечение дискинезии при различных расстройствах
CY1112637T1 (el) Παραγων για την προληψη και αγωγη των παθησεων του ηπατος περιεχοντας παραγωγο πυραζολοπυριμιδινης
UA96622C2 (ru) Твердые лекарственные формы, которые содержат алискирен, изготовленные способом сухого гранулирования
SE0102440D0 (sv) New compound
DE60233276D1 (de) Verfahren zur Herstellung der Natrium Salze von Retinoylderivaten
UY30847A1 (es) Uso de derivados de mononitrato de dianhidrohexita como agentes para el tratamiento de trastornos intestinales
SE0401655D0 (sv) New compounds
NO20090067L (no) Farmasoytiske kombinasjoner for behandling av respiratoriske sykdommer
DE60131416D1 (de) Chirale fluorochinolizinon arginine salze
SE0202311D0 (sv) Novel compounds, cytotoxic preparations comprising said compounds, methods of manufacture of said preparations, as well as methods of treatment
BR0116653A (pt) Medicamento contendo uma poliamina como substância ativa
WO2004100893A3 (en) Methods for treatment of inflammatory diseases using ct-3 or analogs thereof
BRPI0512151A (pt) solução concentrada de sal de sódio monoidratado do tenatoprazol, composição farmacêutica, utilização do sal de sódio monoidratado do tenatoprazol, processo de preparação do sal de sódio monoidratado do tenatoprazol, e composição para administração por via oral do sal de sódio monoidratado do tenatoprazol
MX2023001572A (es) Formas farmaceuticas sólidas de palbociclib.
DE60314920D1 (de) Benzochinolizin-2-carbonsäureargininsalz- tetrahydrat
MXPA05007253A (es) Sales novedosas de derivados anticonvulsivantes.